Tenaya Therapeutics TNYA
NASDAQ TNYA
$0.37 +0.00 (+0.16%)
At close: Nov 11, 2026 · 4:00 PM EST

Tenaya Therapeutics (TNYA) Return on Sales [ROS] (2026)

Updated

Tenaya Therapeutics (TNYA) recorded Return on Sales [ROS] of -1153.33% in Q3 2026, up 2818.56 percentage points from the prior quarter.

Analysis

Tenaya Therapeutics (TNYA) Return on Sales [ROS] (2026) Analysis & Trends

On a TTM basis, Tenaya Therapeutics' Return on Sales [ROS] came in at -3446.57% as of Sep 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Tenaya Therapeutics 84.33 Mn 17.53 Mn - -1,153.33%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -1,153.33%
Jun 30, 2026 -3,971.89%
Mar 31, 2026 -8,917.78%
API Access

Tenaya Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TNYA&period=max&api_key=YOUR_API_KEY